Literature DB >> 16111482

Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998.

Rolf Haye1, Liv Kari Døsen.   

Abstract

BACKGROUND: Previously we treated patients with insect sting allergy with venom immunotherapy (IT) using whole body insect extracts. From 1980 we changed to insect venoms. The purpose of this study was to analyse data from the patients in order to improve our treatment.
METHODS: This is an open, single centre study on patients treated with venom IT 14 years or older with a history of a systemic allergic reaction to an insect sting, a positive skin prick test (SPT) or a positive RAST and willingness to comply with five years of IT. Clinical and laboratory data were registered prospectively at the start of IT and after five years of treatment until 2003 on patients who started IT between 1980 and 1998. Questionnaires were answered in 1989, 1993 and 2003. Statistical analysis was done with Pearson's chi square, Fisher's exact or the t-test.
RESULTS: Of 315 patients treated, 44 were given bee, 248 common wasp and 23 both venoms. Of the common wasp sting incidents 5.5 % resulted in a severe allergic reaction (SAR) during adequate IT and 22% after cessation. Seventy-one per cent of the patients carried epinephrine. Precautionary steps were taken by 77% of the patients during or after inadequate IT. On or after adequate IT 83% felt completely or substantially safe. Surprisingly 29 % of those inadequately treated felt safer and 50% were satisfied with having had the opportunity to be treated. The SPT became negative in 68% of the wasp allergic patients after five years of adequate IT. Increased risk of experiencing SAR to a future sting in wasp allergic patients after cessation of adequate IT was significantly associated with a SAR due to IT during the rush regimen. SAR due to IT occurred very rarely during maintenance dosing.
CONCLUSION: Adequate venom IT is very effective while ongoing but somewhat less effective after cessation, while inadequate treatment gives poor results. More of our patients should complete five years of IT and some should continue IT. The type of reaction to IT during incremental dosing may be of help in deciding who should continue beyond five years. Maintenance IT may be taken over by the general physician.

Entities:  

Year:  2005        PMID: 16111482      PMCID: PMC1208928          DOI: 10.1186/1476-7961-3-12

Source DB:  PubMed          Journal:  Clin Mol Allergy        ISSN: 1476-7961


  21 in total

1.  Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology.

Authors:  H Mosbech; U Müller
Journal:  Allergy       Date:  2000-11       Impact factor: 13.146

2.  [Wasp allergy vaccination].

Authors:  Helge Røvik Røsjø; Johannes Espolin Johnson Hov; Fredrik Borchsenius; Ole Henning Skjønsberg
Journal:  Tidsskr Nor Laegeforen       Date:  2003-04-10

3.  [Insect allergy. Hyposensitization with insect venoms in 1980-1987].

Authors:  R Haye
Journal:  Tidsskr Nor Laegeforen       Date:  1988-10-20

4.  Dose dependence of Hymenoptera venom immunotherapy.

Authors:  D B Golden; A Kagey-Sobotka; M D Valentine; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1981-05       Impact factor: 10.793

5.  Natural history of allergy to Hymenoptera.

Authors:  G A Settipane; F H Chafee
Journal:  Clin Allergy       Date:  1979-07

6.  Insect sting-inflicted systemic reactions: attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine.

Authors:  A Goldberg; R Confino-Cohen
Journal:  J Allergy Clin Immunol       Date:  2000-12       Impact factor: 10.793

7.  Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.

Authors:  H K van Halteren; P W van der Linden; J A Burgers; A K Bartelink
Journal:  J Allergy Clin Immunol       Date:  1997-12       Impact factor: 10.793

Review 8.  Quality of life in insect venom allergic patients.

Authors:  Joanne N G Oude Elberink; Anthony E J Dubois
Journal:  Curr Opin Allergy Clin Immunol       Date:  2003-08

9.  Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.

Authors:  J Birnbaum; D Charpin; D Vervloet
Journal:  Clin Exp Allergy       Date:  1993-03       Impact factor: 5.018

10.  Comparison of the Phadebas RAST with the Pharmacia CAP system for insect venom.

Authors:  S Jeep; E Kirchhof; A O'Connor; G Kunkel
Journal:  Allergy       Date:  1992-06       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.